MiNK Therapeutics Reports First Product Revenue of $0.2 Million and Net Loss of $2. ...
Q3 2026 revenue of $0.2 million trails the $0.88 million consensus, while a narrower loss per share comes in above the estimate Related Stocks: INKT ,
Q3 2026 revenue of $0.2 million trails the $0.88 million consensus, while a narrower loss per share comes in above the estimate Related Stocks: INKT ,